Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CBS | P35520 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938805 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL17938809 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL2464261 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL17938765 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL17938807 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL2370035 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL16535327 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL11296037 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL11296041 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 | |
| SCHEMBL17938820 | 1.00 | PTGS2 (0.48) | PTGS2LCKCBSCYP3A4TNNC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240355451-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | NESTLE SA (CH) | 2024-10-24 | — | — | US | disclosed |
| US-20240216296-A1 | POLYPHENOL COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY | EPICEUTICAL LABS LLC | 2024-07-04 | — | — | US | disclosed |
| EP-4391834-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240101791-A1 | POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059282-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023025722-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2023-03-02 | — | — | WO | disclosed |
| US-9901595-B2 | Glycan therapeutics for reducing blood ammonia | KALEIDO BIOSCIENCES, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9757403-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170246201-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| WO-2017035412-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3071235-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016122889-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216296-A1 | POLYPHENOL COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY | FABP2, HDLBP, FABP1 | PTGS2 1736/4885LCK 3951/4885CBS 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.